Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

Share Price is delayed by 15 minutes
Get Live Data
222.00    -5.00 (-2.20%)
Bid:
222.00
Ask:
232.00
Spread: 10.00 (4.505%)
Market Cap: £117.21m
APTD Live PriceLast checked at - London Stock Exchange

Intraday Aptitude Share Chart

Interim Management Statement

13 May 2013 07:00

RNS Number : 4884E
Microgen PLC
13 May 2013
 



microgen

www.microgen.com

 

13 May 2013

 

INTERIM MANAGEMENT STATEMENT

 

 

Microgen plc ('Microgen' or 'Group') provides its Interim Management Statement covering the period from 1 January 2013 to the date of this announcement. Microgen released its final results for the year ending 31 December 2012 on 25 February 2013.

 

There have been no significant changes since 1 January 2013 in the financial position of Microgen and its balance sheet remains strong. The Group had net cash at 30 April 2013 of £32.3 million (31 December 2012 : £32.1 million) before payment of the dividend and special dividend totalling £6.1 million, scheduled for 28 May 2013.

 

The Board remains satisfied with the financial performance of the Group with benefit continuing to be received from its conservative operational approach and annual licencing model. The Financial Systems Division has commenced delivery of a significant 5Series project with a large global bank and continues to perform satisfactorily. The Microgen Aptitude Solutions Division ("MASD") has started implementation of a major new financial services project in North America based on both Microgen Aptitude and Accounting Hub. In addition, MASD has further strengthened its intellectual property portfolio with three new patents being granted by the US Patent Office since 1 January 2013 in respect of the Microgen Aptitude technology.

 

Strategic Review

 

The Microgen Group continues to be financially very robust with a strong balance sheet and consistent profitability/cash flow. Following payment of the dividend and special dividend, through the Board's pro-active shareholder realisation programme, Microgen will have returned to shareholders 100% of the market capitalisation as at 13 October 2008 via dividends, special dividends, tender offers and share buy-backs.

 

The Microgen Aptitude technology and related applications (e.g. Microgen Accounting Hub) continue to be affirmed as being market leading. Originally targeted at the financial services sector, which remains the core of the business, Microgen Aptitude has also established a strong reputation in the digital media sector and is now developing opportunities in both the telecom and healthcare sectors.

 

The Financial Systems Division operates in more established product categories with high recurring revenues. The core business which operates within the financial services sector has been stable for a number of years and continues to provide predictable cash flows. Furthermore, the investment in the development of the 5Series Trust & Fund administration product and an increasingly active wealth management market, have resulted in a number of new customer wins during the past year as well as upgrades from the previous 4Series product version.

 

Notwithstanding these strengths and the success of the shareholder realisation programme since October 2008, Microgen is constrained as a result of being a small, independent public company. As a provider of enterprise solutions in a risk-averse market environment, the size of the group can be an inhibitor given the very large enterprise software companies with which MASD typically competes. As a result, the Board has determined this to be an appropriate time to evaluate the Group's future strategy to maximise the potential of Microgen's market-leading technology and applications and has therefore decided to undertake a strategic review of the Group.

 

Given the financial strength of Microgen, continuing with the current strategy and structure remains a viable option. Nevertheless, the strategic review will be wide-ranging and may, or may not, result in the disposal of one or both of the operating divisions. Alternatively, the Board will also consider the merits of acquisition(s) to increase the scale of the Group, including acquisition(s) which may or may not provide operating synergies with the current operating divisions. Investec Bank Plc has been appointed to assist the Board in the strategic review.

 

The Board anticipates that this process will take several months. Further announcements will be made as appropriate.

 

 

 

 

 

 

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

David Sherriff, Chief Executive Officer

Philip Wood, Group Finance Director

 

James Melville-Ross, FTI Consulting 020-7831-3113

Lucy Delaney, FTI Consulting

 

Rowena Murray, Investec Bank Plc 020-7597 5970

Andrew Pinder, Investec Bank Plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSAMMATMBABBTJ
Date   Source Headline
6th Aug 20247:00 amRNSTransaction in Own Shares
2nd Aug 20247:00 amRNSTransaction in Own Shares
1st Aug 202410:07 amRNSTotal Voting Rights
1st Aug 20247:00 amRNSTransaction in Own Shares
31st Jul 20247:00 amRNSTransaction in Own Shares
30th Jul 20247:00 amRNSTransaction in Own Shares
25th Jul 20247:00 amRNSInterim Results
25th Jul 20247:00 amRNSTransaction in Own Shares
24th Jul 20247:00 amRNSTransaction in Own Shares
23rd Jul 20247:00 amRNSTransaction in Own Shares
18th Jul 20247:00 amRNSTransaction in Own Shares
15th Jul 20247:00 amRNSTrading Update and Notice of Results
12th Jul 20247:00 amRNSTransaction in Own Shares
8th Jul 20247:00 amRNSTransaction in Own Shares
4th Jul 20247:00 amRNSTransaction in Own Shares
3rd Jul 20247:00 amRNSTransaction in Own Shares
2nd Jul 20247:00 amRNSTransaction in Own Shares
1st Jul 20247:00 amRNSTotal Voting Rights
1st Jul 20247:00 amRNSFynapse contract win with major existing client
1st Jul 20247:00 amRNSTransaction in Own Shares
28th Jun 20247:00 amRNSTransaction in Own Shares
27th Jun 20247:00 amRNSTransaction in Own Shares
26th Jun 20247:00 amRNSNotification of Major Holdings
18th Jun 20247:00 amRNSFynapse Investor Insights Session
17th Jun 20247:00 amRNSFynapse contract win in partnership with HSO
17th Jun 20247:00 amRNSTransaction in Own Shares
6th Jun 20247:00 amRNSTransaction in Own Shares
5th Jun 20247:00 amRNSTransaction in Own Shares
3rd Jun 202411:03 amRNSTotal Voting Rights
3rd Jun 20247:00 amRNSTransaction in Own Shares
28th May 20247:00 amRNSTransaction in Own Shares
24th May 20247:00 amRNSTransaction in Own Shares
20th May 20244:38 pmRNSNotification of Major Holdings
20th May 20247:00 amRNSTransaction in Own Shares
17th May 20247:00 amRNSTransaction in Own Shares
15th May 20247:00 amRNSTransaction in Own Shares
14th May 202410:48 amRNSResult of AGM
14th May 20247:00 amRNSAGM Statement
10th May 20247:00 amRNSTransaction in Own Shares
8th May 20247:00 amRNSNotification of Major Holdings
8th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
1st May 20244:10 pmRNSTotal Voting Rights
30th Apr 20244:46 pmRNSGrant of awards under 2020 Deferred Bonus Plan
29th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.